Surgical robotics include soft-tissue platforms (Intuitive da Vinci, J&J Ottava, Medtronic Hugo, Asensus Senhance), orthopedic systems (Stryker Mako, Zimmer ROSA, Smith+Nephew CORI), spine (Globus ExcelsiusGPS, Medtronic Mazor), and emerging endoluminal/bronchoscopy robots (Intuitive Ion, J&J Monarch). Systems are usually cleared through 510(k) or De Novo, with indications tied to specific procedures. Business models combine capital sales or leases with instruments and service. Training, operating room workflow and cost per procedure are key adoption factors.

Why it matters

Razor/razor-blade economics - capital placement drives recurring instruments and accessories revenue. Capital cycles, hospital budgets, and ASC adoption now shape growth more than clinical evidence.

Common pitfalls

•A common pitfall is underestimating the complexity of software validation for robotic surgical systems, particularly for AI/machine learning components, as required by IEC 62304.
•Failing to adequately address cybersecurity risks throughout the entire lifecycle of the robot, from design to post-market surveillance, can lead to vulnerabilities and regulatory non-compliance.
•Insufficient human factors engineering can result in use errors, impacting patient safety and leading to regulatory scrutiny.
•Not clearly defining the intended use and potential off-label uses of the robotic system can create significant regulatory challenges.
•Overlooking the need for robust post-market surveillance and vigilance systems specifically tailored for robotic devices is a common oversight.

Sources

Society of Robotic Surgery · SRS
AdvaMed - Industry Reports · AdvaMed
MedTech Europe - Facts & Figures · MedTech Europe
Computer-Assisted Surgical Systems · FDA

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.